173774-48-6

Basic information

• Product Name: (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID
• Synonyms: (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID;1,2,4-Piperazinetricarboxylic acid, 1,4-bis(1,1-diMethylethyl) ester, (2R)-
• CAS NO: 173774-48-6
• Molecular Formula: C₁₅H₂₆N₂O₆
• Molecular Weight: 330.378
• Mol File: 173774-48-6.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 443.888 °C at 760 mmHg
• Flash Point: 222.256 °C
• Appearance: /
• Density: 1.201 g/cm³
• Refractive Index: 1.503
• Storage Temp.: 2-8°C
• PKA: 3.70±0.20(Predicted)
• CAS DataBase Reference: (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID(173774-48-6)
• EPA Substance Registry System: (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID(173774-48-6)

Safety Data

• Hazardous Substances Data: 173774-48-6(Hazardous Substances Data)

Usage

General Description

(R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID is a chemical compound belonging to the category of piperazine carboxylic acids. It is a derivative of piperazine and is commonly used as a building block in the synthesis of various pharmaceutical compounds. (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID is often utilized in the development of drugs for the treatment of various disorders and diseases. It contains a BOC (tert-butoxycarbonyl) protecting group on both the nitrogen atoms, which helps in controlling the reactivity of the compound during various chemical reactions. Overall, (R)-1-N-BOC-4-N-BOC-PIPERAZINE-2-CARBOXYLIC ACID plays an important role in the pharmaceutical industry as a key intermediate in the synthesis of therapeutic agents.

InChI:InChI=1/C15H26N2O6/c1-14(2,3)22-12(20)16-7-8-17(10(9-16)11(18)19)13(21)23-15(4,5)6/h10H,7-9H2,1-6H3,(H,18,19)/t10-/m1/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 192330-11-3 (R)-4-(tert-butoxycarbonyl)piperazine-2-carboxylic acid 
• 637027-24-8 (R)-piperazine-1,2,4-tricarboxylic acid 1,4-di-tert-butyl ester 2-methyl ester 
• 31321-68-3 (R)-piperazine-2-carboxylic acid 
• 3022-15-9 piperazine-2-carboxylic acid dihydrochloride 

Downstream Products

• 173774-50-0 N-Boc-piperazine-2-amidoanhydride 
• 892393-40-7 (+)-N₁,N₄-di-(tert-butyloxycarbonyl)-N-[3-[(1H-imidazol-1-yl)-methyl]phenyl]-(2R)-piperazinecarboxamide 
• 892393-42-9 (+)-N₁,N₄-di-(tert-butyloxycarbonyl)-N-[3-[(4-methyl-1H-imidazol-1-yl)methyl]phenyl]-(2R)-piperazinecarboxamide 
• 892393-46-3 (+)-N₁,N₄-di-(tert-butyloxycarbonyl)-N-[3-[(5-methyl-1H-imidazol-1-yl)methyl]phenyl]-(2R)-piperazinecarboxamide 
• 637027-24-8 (R)-piperazine-1,2,4-tricarboxylic acid 1,4-di-tert-butyl ester 2-methyl ester 
• 1159598-21-6 (R)-2-hydroxymethylpiperazine-1,4-dicarboxylic acid di-tert-butyl ester 
• 1361223-95-1 di-tert-butyl (2R)-2-((1-methylethyl)carbamoyl)-1,4-piperazinedicarboxylate 
• 1361223-83-7 di-tert-butyl (2R)-2-((2-methylpropyl)carbamoyl)-1,4-piperazinedicarboxylate 
• 1361218-82-7 di-tert-butyl (2R)-2-(((3S)-3-methyl-4-morpholinyl)carbonyl)-1,4-piperazinedicarboxylate 
• 1361218-83-8 3,3,3-trifluoro-2-(4-((2S)-2-(((3S)-3-methyl-4-morpholinyl)methyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-1,2-propanediol 
• 1361218-85-0 (2R)-3,3,3-trifluoro-2-(4-((2S)-2-(((3S)-3-methyl-4-morpholinyl)methyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-1,2-propanediol 
• 1361218-84-9 (2S)-3,3,3-trifluoro-2-(4-((2S)-2-(((3S)-3-methyl-4-morpholinyl)methyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)phenyl)-1,2-propanediol 
• 1361220-57-6 1,1,1,3,3,3-hexafluoro-2-(4-((2S)-2-(((3S)-3-methyl-4-morpholinyl)methyl)-4-(2-thiophenylsulfonyl)-1-piperazinyl)-phenyl)-2-propanol 
• 1361223-67-7 2-(4-((2S)-4-((5-amino-2-thiophenyl)sulfonyl)-2-(((3S)-3-methyl-4-morpholinyl)methyl)-1-piperazinyl)phenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 

Relevant articles and documents

Bis(vinylsulfonyl)piperazines as efficient linkers for highly homogeneous antibody-drug conjugates

Disulfide re-bridging strategy has demonstrated significant advantages in the construction of homogeneous antibody drug conjugates (ADCs). However, a major issue that disulfide scrambling at the hinge region of antibody leads to the formation of “half-antibody” has appeared for many re-bridging linkers. We present bis(vinylsulfonyl)piperazines (BVP) as efficient linkers to selectively re-bridge disulfides at the antigen-binding fragment (Fab) regions and produce highly homogeneous conjugates with a loading of two drugs without disulfide scrambling. We also found that optically active (S)-configuration linkers led to more sufficient conjugation compared with (R)-configuration. The BVP-linked ADCs demonstrated superior efficacy and antigen-selectivity in vitro cytotoxicity.

HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ABNORMAL CELLULAR PROLIFERATION

This invention is in the area of heterocyclic-based compounds for the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.

Human Adam-10 Inhibitors

Magnesium salts/complexes of compounds useful for inhibiting the ADAM-IO protein and methods of making and purifying them are provided. Further provided are compositions comprising magnesium salts/complexes of the compounds in combination with a pharmaceutically acceptable carrier. The compounds well as such compositions comprising them are useful for the treatment of cancer, arthritis, diseases related to angiogenesis, such as renal diseases, heart diseases, such as heart failure, atherosclerosis, and stroke, inflammation, ulcer, infertility, scleroderma, endometriosis, mesothelioma, and diabetes. In addition, methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role are provided.